Simulations Plus to Present at the Sidoti Semi-Annual New York Micro-Cap Conference
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting
services and software for pharmaceutical discovery and development,
today announced that Walt Woltosz, chairman and chief executive officer,
will present at the Sidoti & Company Semi-Annual New York Micro-Cap
Conference at 11:20 a.m. Eastern Time on Monday, January 7, 2013, in
Estate 6 (Uris Room) at the Grand Hyatt New York Hotel.
Simulations Plus management will be available during the day for
one-on-one meetings. To schedule a meeting, please contact your Sidoti
representative. A copy of the investor presentation that will accompany
management’s group presentation will be available at the Simulations
Plus corporate website - www.simulations-plus.com
- prior to the presentation.
Sidoti & Company, LLC
Sidoti & Company, LLC Micro-Cap Conference is one of the largest
micro-cap focused investor events in the U.S., with over 400
institutional investor attendees at the previous micro-cap conference.
For more information or to register for the conference, please visit http://microcap.sidoti.com.
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug
discovery and development simulation software, which is licensed to and
used in the conduct of drug research by major pharmaceutical and
biotechnology companies worldwide. For more information, please visit www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995 – With the exception of historical information, the
matters discussed in this press release are forward-looking statements
that involve a number of risks and uncertainties. Words like “believe,”
“expect” and “anticipate” mean that these are our best estimates as of
this writing, but that there can be no assurances that expected or
anticipated results or events will actually take place, so our actual
future results could differ significantly from those statements. Factors
that could cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the pharmaceutical
industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, our ability to
identify and close acquisitions on terms favorable to the Company, and a
sustainable market. Further information on our risk factors is contained
in our quarterly and annual reports as filed with the Securities and
Exchange Commission.
